Roots Analysis Identifies Nine Leading ADC Technology Providers
Market research firm Roots Analysis has released a report identifying nine key players providing linker and conjugation technologies for antibody drug conjugate (ADC) development.
In September 2023, Roots Analysis published a report highlighting nine prominent companies in the field of linker and conjugation technologies for antibody drug conjugates (ADCs). These technologies are crucial for the efficacy and safety of these targeted cancer therapies.
ADCs have gained significant traction in oncology and hematology treatments, with 14 approved products currently on the market. An additional 400-plus ADC candidates are in clinical or preclinical development. The firm's analysis reviewed over 65 technology providers, identifying nine key players across North America and Europe.
The choice of linkers and conjugation technologies within the manufacturing process significantly impacts an ADC's characteristics, such as its effectiveness and precision. Traditional methods utilizing lysine or cysteine residues are increasingly being supplemented by site-specific conjugation techniques, which enhance drug homogeneity and stability.
The identified companies include Ambrx, Antikor, Catalent Biologics, Iksuda Therapeutics, Heidelberg Pharma, Mersana Therapeutics, NBE-Therapeutics, Seagen (formerly Seattle Genetics), and Sutro Biopharma. The technologies offered by these firms support the development of new and more potent ADC therapeutics.
Roots Analysis stated that collaborations between these technology providers and drug development firms are essential for the success of this drug class. The firm has analyzed the market landscape and future opportunities within the technology sector over a 12-year period.